Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
15.76
+0.32 (2.06%)
Mar 9, 2026, 1:35 PM EDT - Market open
Pharming Group Revenue
Pharming Group had revenue of $97.29M in the quarter ending September 30, 2025, with 29.98% growth. This brings the company's revenue in the last twelve months to $362.27M, up 26.78% year-over-year. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm)
$362.27M
Revenue Growth
+26.78%
P/S Ratio
2.92
Revenue / Employee
$896,718
Employees
404
Market Cap
1.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| AbCellera Biologics | 75.13M |
| Inventiva | 19.93M |
| uniQure | 16.10M |
| Aktis Oncology | 5.56M |
| Inhibrx Biosciences | 1.40M |
PHAR News
- 5 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - GlobeNewsWire
- 10 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 11 days ago - Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 - GlobeNewsWire
- 17 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 19 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - GlobeNewsWire
- 20 days ago - Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - Pharming Group: Crossing From Speculation To Profitability - Seeking Alpha
- 4 weeks ago - Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript - Seeking Alpha